Yi Larson, M.Eng., MBA

Yi Larson is the Founder and CEO of Expedition Therapeutics Inc. She brings over 20 years of leadership experience across biotechnology, finance, and strategy. Previously, she served as CFO of LianBio and as Executive Vice President and CFO of Turning Point Therapeutics, where she helped guide the company through its $4.1 billion acquisition by Bristol Myers Squibb. Earlier, Ms. Larson spent more than a decade at Goldman Sachs as Managing Director in Healthcare Investment Banking, advising on over 50 transactions totaling more than $100 billion in M&A and financings. She currently serves on the Board of Olema Oncology and previously served on the Board of RayzeBio, acquired by Bristol Myers Squibb in 2024. Ms. Larson holds an MBA in Finance from The Wharton School and bachelor’s and master’s degrees in Electrical Engineering and Computer Science from MIT.